Journal article

Peptide hormone analysis in diagnosis and treatment of Differences of Sex Development: joint position paper of EU COST Action & lsquo;DSDnet & rsquo; and European Reference Network on Rare Endocrine Conditions

TH Johannsen, A-M Andersson, SF Ahmed, YB de Rijke, RF Greaves, MF Hartmann, O Hiort, P-M Holterhus, NP Krone, A Kulle, ML Ljubicic, G Mastorakos, J McNeilly, AM Pereira, A Saba, SA Wudy, KM Main, A Juul



Differences of Sex Development (DSD) comprise a variety of congenital conditions characterized by atypical chromosomal, gonadal, or anatomical sex. Diagnosis and monitoring of treatment of patients suspected of DSD conditions include clinical examination, measurement of peptide and steroid hormones, and genetic analysis. This position paper on peptide hormone analyses in the diagnosis and control of patients with DSD was jointly prepared by specialists in the field of DSD and/or peptide hormone analysis from the European Cooperation in Science and Technology (COST) Action DSDnet (BM1303) and the European Reference Network on rare Endocrine Conditions (Endo-ERN). The goal of this position pap..

View full abstract


Awarded by EU-program Horizon 2020

Awarded by Third European Union's Health Programme (CHAFEA)

Funding Acknowledgements

The COST (European Cooperation in Science and Technology) Action DSDnet received funding under the EU-program Horizon 2020 (Reference BM1303). Endo-ERN is a European Reference Network co-funded by the Third European Union's Health Programme (CHAFEA Framework Partnership Agreement number: 739527 -Endo-ERN).